HBM Partners is among the global leaders in healthcare-focused investing with approximately USD 1.5 billion under management. HBM focuses on development stage, growth and buy-out financings of private companies as well as investments in public companies. HBM Partners advises HBM Healthcare Investments AG, HBM BioCapital and further specialized private-equity and public-equity funds. HBM has a complementary team of experienced professionals to source, analyze, execute and exit investments in the pharma/biotech, medical devices and diagnostics industries. HBM Partners has been an active contributor to value creation in its portfolio companies, generating over 40 trade sales and IPOs since inception.
As an independent supervisory authority, FINMA acts to protect the interests of creditors, investors and insured persons and to ensure the proper functioning of the financial markets. FINMA approves and supervises the financial market participants. Following the revision of the Swiss collective investment schemes act, HBM Partners applied for an asset manager and representative license and has become subject to supervision by FINMA in February 2015. The authorization as asset manager also includes the license as distributor. As such, it is in compliance with all regulatory and legal requirements placed to manage and distribute collective investment schemes in Switzerland.
© HBM Partners AG